I'm delighted to announce that the results of the ASTER 70s trial have just been published in the prestigious journal, The Lancet!
ASTER 70s is the first phase 3 superiority trial investigating the benefit of chemotherapy versus no chemotherapy in the adjuvant setting specifically in women aged 70 years or older with oestrogen receptor-positive breast cancer and at high risk according to genomic grade index (GGI)
The addition of adjuvant chemotherapy to hormonotherapy conferred no statistically significant survival benefit and was associated with more adverse events and worse Health-related Quality of Life.
The ASTER 70s trial provides important information to improve shared decision making between doctor and patient when discussing adjuvant breast cancer treatment.
Despite a large clinical and geriatric assessment deployed in the trial, no subgroup has been identified to more precisely define patients who really benefit from chemotherapy addition to hormonotherapy.
A huge translational research program on tumor and blood samples is now ongoing: ASTER-T (PRTK-23) and ASTER predict (FONDATION ARC-24)
My sincere thanks to Prof. Etienne BRAIN from Institut Curie for the constant trust in the UMQVC and for the consideration of the role, work and essential commitment of the methodologist and statistician in clinical and translational research.
Special thoughts to the great working group composed of Telma ROQUE and Jerome Lemonnier from Unicancer and my colleague Julie Henriques from UMQVC
A propos de Dewi VERNEREY
Dewi Vernerey is a research engineer in epidemiology and biostatistics who received a master’s degree cum laude from Joseph Fourier University (Grenoble, France) with a major in engineering statistics. He defended a PhD in epidemiology and statistics in 2016. His PhD research focused on statistical methodology for risk prediction and prognostic score construction in oncology and kidney transplantation.